ASH 2025: Eli Lilly’s Jaypirca emerges as a strong first-line contender in CLL/SLL
Lilly’s Jaypirca scores big in first-line CLL/SLL, cutting progression risk by 80% and challenging rival BTK inhibitors.
Themes
Redefining clinical trials in oncology and rare diseases across the Europe
ESMO 2025: potential new adjuvant option ensartinib for ALK+ NSCLC
Asbestos-related cancers still prevalent in the UK
Cognivia’s AI software predicts probability of trial patient dropping out
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer
Sartorius to invest $3m for minority share in biotech start-up Nanotein
GSK’s anti-TIM-3 antibody fails in Phase III NSCLC trial
